WT1 was first identified as a tumor suppressor involved in the development of Wilms' tumor.
Recently, oncogenic properties of WT1 have been demonstrated in various hematological
malignancies and solid tumors. Because WT1 has been identified as a molecular target for
cancer immunotherapy, immunohistochemical detection of WT1 in tumor cells has become
an essential part of routine practice. In the present study, the expression of WT1 was
examined in 494 cases of human cancers, including tumors of the gastrointestinal and …